Day 2 - Friday 5th May 2023
9th RWE, Market Access, Pricing & Reimbursement Global Congress 2023 Europe
Trends and Strategies to Achieve Optimum Patient Access to Healthcare
Ana Plata, Global Pricing Head – BioPharmaceuticals, AstraZeneca
CHALLENGES & OPPORTUNITIES
- Advantages of market access teams in payer relationship
- Payer evidence requirement in early development
- Best practices to obtain better pricing and reimbursement
- Strategies to improve a better payer relationship
Claudia Neuber, Head, Global Pricing Oncology, Global Market Access & Pricing, AstraZeneca
- Access to innovative medicines remains a key issue worldwide
- Limitations of the some of the initiatives to address this such as the EUnetHTA JCA and the expected change in legislation in Europe
- How can pharmaceutical companies and health authorities work together to bridge the gap
Silvy Mardiguian, Market Access Director, UK & Ireland, BeiGene UK
- Innovative approaches required to address the medicine access challenge
- Lessons to be learned from best practices in the field of pricing and reimbursement of medicines
- The value of list prices against the backdrop of external price referencing and managed entry agreements.
- Innovative policy options that needs to be developed, agreed upon and implemented.
Josie Godfrey, Co-Founder and CEO, Realise Advocacy, Director, JG Zebra Consulting
- One of the most overlooked activities in the entire market access flow is tendering, a successful access is measured
on how the medicine reaches the patients, however an increasing amount of countries are using tenders to add
additional pressure on the procurement of the therapies, not having an adequate process in place can jeopardize
access plans and can have unexpected consequences abroad
Frankie Shupo, Global Director, Market Access and HEOR, EUSA Pharma
- Role of market access within the organization and importance of market access capabilities;
- Building “market access mindset” for cross-functional business partners;
- Evolving capabilities for future market access leaders
Maria Danchenko, Global Market Access Academy Lead, Sanofi
Daniel Jackson, Global Head – Market Access Policy, UCB
- Challenges in drug pricing and reimbursement
- How to navigate a complex balance between financial and strategic risks
- Strategies to offset regulatory and inflationary pressures.
- Addressing environmental, social, and corporate governance issues
- Encouraging cross-functional or cross-company collaborations
Antje Emmermann, Executive Director, Market Access Lead, Alexion
- One of the most overlooked activities in the entire market access flow is tendering, a successful access is measured
on how the medicine reaches the patients, however an increasing amount of countries are using tenders to add
additional pressure on the procurement of the therapies, not having an adequate process in place can jeopardize
access plans and can have unexpected consequences abroad.
Ryotaro Ishikawa, Global Market Access Director, Novartis
- As innovation brings cancer drugs & curative medicines to the forefront of healthcare systems, how are payers affording to pay for this innovation ?
- what are the new determinants of value in healthcare, and the geopolitical drivers for value based agreements & innovative contracting ?
- If the drugs dont work – I want my money back! – access into a global tracker of over 700 innovative contracts from around the globe
- Who’s shifting the paradigm – adoption curves for those manufacturers leading the way in capabilities for innovative contracting
Omar Ali, Visiting Lecturer Value Based Pricing & Innovative Contracting of New Medicines, University of Portsmouth
- The importance of making MA the core of the company
- Bridge between pre-launch strategy and post-launch
- International Drug Price Indicator Guide WHO
- Increasing collaboration between EU countries
- Frontiers in Health Care
- What will the future bring?
Panelist:
Maria Danchenko, Global Market Access Academy Lead, Sanofi
Daniel Jackson, Global Head – Market Access Policy, UCB
